Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.4
11.11%
40%
—
152.68%
40%
—
5 Years
Score4.4
Net Growth11.11%
Net Trend40%
Net Income Consistency—
Rev Growth152.68%
Rev Trend40%
Revenue Consistency—
Verrica Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 12M to $ 35M and net income went from -$ 45M to -$ 17M. Revenue increased in 2 of those 5 years; net income in 2.
Verrica Pharmaceuticals Inc currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 5.09 | — |
1 Year2025-08-12 | $ 6.82 | -25.37% |
5 Years2021-08-12 | $ 106.90 | -95.24% |
All Time2018-06-15 | $ 175.00 | -97.09% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-06-15 |
|---|---|---|---|---|
| Price | $ 5.09 | $ 6.82 | $ 106.90 | $ 175.00 |
| Return | — | -25.37% | -95.24% | -97.09% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 30M | -$ 31M | $ 11M |
| 2025 | $ 35M | -$ 17M | $ 30M |
| 2024 | $ 7M | -$ 76M | $ 46M |
| 2023 | $ 5M | -$ 66M | $ 69M |
| 2022 | $ 9M | -$ 24M | $ 34M |
| 2021 | $ 12M | -$ 35M | $ 70M |
| 2020 | $ 12M | -$ 45M | $ 65M |
| 2019 | $ 0.00 | -$ 27M | $ 62M |
| IPO2018 | $ 0.00 | -$ 20M | $ 89M |
Explore beyond VRCA
You're looking at Verrica Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
